Primo Brands Corporation Class A Common Stock vs Zoetis Inc — how do they compare? Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.80B), while Zoetis Inc trades at $76.19 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 4.6× Primo Brands Corporation Class A Common Stock's market cap, and Zoetis Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold Primo Brands Corporation Class A Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| PRMB | ZTS | |
|---|---|---|
Market Cap | $6.80B | $31.11B |
Volume | 3,695,669 | 2,515,954 |
Sector | Consumer Staples | Health |
52-Week High | $25.39 | $147.53 |
52-Week Low | $14.46 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $12.13B | $38.68B |
Dividend Yield | 2.56% | 2.82% |
Signals from Pluang's Aura AI — not financial advice
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →